论文部分内容阅读
[目的]评价低分子量肝素对活动性溃疡性结肠炎的有效性及安全性.[方法]利用EMBASE、PubMed、Cochrane Library、CNKI、CBM、VIP、WANFANG DATA等数据库检索建库以来至2018年4月的相关文献,制定严格纳入、排除标准,进行文献筛选,并对研究指标进行数据提取,采用Revman 5.3软件进行统计学处理.[结果]11项随机对照试验(randomized contrdled trials,RCTs)研究符合纳入标准,共计活动性溃疡性结肠炎842例,包括试验组419例,对照组423例.Meta分析结果示:试验组总有效率高于对照组,差异有统计学意义[OR=2.5,95％CI(1.74,3.61),P＜0.01],完全缓解率高于对照组,差异有统计学意义[OR=1.64,95％CI(1.32,2.04),P＜0.01],不良反应发生率与对照组比较差异无统计学意义[OR=0.97,95％CI(0.63,1.51),P=0.91].[结论]低分子量肝素用于治疗活动性溃疡性结肠炎有一定疗效,且安全性较好,无严重不良反应发生.“,”[Objective]To evaluate the efficacy and safety of low molecular weight heparin(LMWH)in the treatment of active ulcerative colitis.[Methods]EMBASE,PubMed,Cochrane Library,CNKI,CBM, VIP,WANFANG DATA and other databases were used to retrieve the relevant documents from the database before April 2018.The strict inclusion and exclusion criteria were formulated and the literature was screened.The data were extracted and the statistical processing was carried out by Revman 5.3software. [Results]The study of 11randomized controlled trials(randomized Contrdled trials,RCTs)accorded with the inclusion criteria involved total active UC in 842cases,including 419in the experimental group and 423 in the control group.The results of meta analysis showed that the total effective rate of the test group was higher than that of the control group.The difference was statistically significant(OR=2.5,95％CI[1.74, 3.61]andP＜0.01),and the total remission rate was higher than that of the control group.The difference was statistically significant(OR=1.64,95％CI[1.32,2.04],P＜0.01),and there was no significant difference in the incidence of adverse reaction between the control group and the control group(OR=0.97,95％ CI[0.63,1.51],P=0.91).[Conclusion]LMWH is effective and safe in the treatment of active UC without serious adverse reactions.